Revance Therapeutics (RVNC)

FAQ for $RVNC investors Q:What is this settlement about? A: Revance Therapeutics agreed to a $17M settlement over claims the company misled investors about its relationship with Teoxane and the delayed Crown tender offer. Q: Who may qualify? A: Investors who purchased or acquired $RVNC securities between Feb. 29, 2024 and Feb. 6, 2025. Q: What’s the deadline? A: The claim deadline is Aug. 28, 2026. Q: What happened to the stock? A: After disclosures about the Teoxane dispute and revised merger terms, Crown cut its offer price from $6.66/share to $3.10/share. Q: Is my data safe with 11th Estate? A: Security is our top priority. We use bank-level encryption and are SOC2-compliant. We only process the trade data required for the court audit, and your personal financial credentials stay private. Q: What is the fee? A: We work on a 20% success fee. We handle the math, the paperwork, and the filing. If you don't get a payout, you don't pay us a cent. Q: How do I start? A: Just click the link below to submit your claim through our secure portal. https://11th.com/cases/revance-investor-settlement

The $17 million Revance Therapeutics ($RVNC) deadline is August 28, 2026 If you bought shares between February 29, 2024, and February 6, 2025, you are likely eligible for the $17 million recovery fund. This settlement resolves claims that Revance Therapeutics misled investors regarding its Teoxane dispute, delayed Crown tender offer, and related stock-price declines. The stock dropped following the disclosure, and now the company is paying back to impacted shareholders ($0.16 per share). File your claim here: https://11th.com/cases/revance-investor-settlement

$RVNC — Updates for the Revance Therapeutics investor settlement The settlement has just received preliminary approval, and you can already submit a claim to get payment. 📌 What happened? Revance allegedly misled investors about the strength and sustainability of its Teoxane partnership and overall sales performance. The issue came to light when a breach notice, stricter contract terms, and financial concerns were disclosed, leading to a reduced acquisition offer and significant pressure on the company’s outlook. ❓ Who qualifies? Buyers of $RVNC between February 29, 2024, and February 6, 2025, inclusive. ➡️ Apply now: https://11th.com/cases/revance-investor-settlement

$RVNC this was a sure thing at $25

$RVNC penny land inbound

$RVNC Hahahahahahah...

Wall St is expecting -0.30 EPS for $RVNC Q1 [Reporting 05/08 AMC] http://www.estimize.com/intro/rvnc?chart=historical&metric_name=eps&utm_c

$RVNC I’m going to have a $TELL 2.0 delisting ceremony. I hope Foley has to sell his house like Souki.

$RVNC Crown Laboratories Announces Completion of Acquisition of Revance Therapeutics Currently t-12 halted

https://www.prnewswire.com/news-releases/the-gross-law-firm-notifies-shareholders-of-revance-therapeutics-incrvnc-of-a-class-action-lawsuit-and-an-upcoming-deadline-302369534.html $RVNC